Search

Search Constraints

You searched for: Author/Creator Short, Nicholas J.

Search Results

11. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations. Issue 3 (29th October 2020)

12. Clinical characteristics and outcomes of previously untreated patients with adult onset T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma with hyper‐CVAD based regimens. Issue 10 (29th July 2017)

13. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission. Issue 11 (8th September 2022)

14. Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment. Issue 11 (15th September 2022)

15. De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Issue 12 (5th April 2021)

16. Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia. Issue 5 (19th February 2021)

17. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Issue 11 (19th August 2021)

18. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia. Issue 2 (7th September 2016)

19. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Issue 6 (17th March 2022)

20. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Issue 14 (1st April 2021)